

November 2006 Extraordinary meeting PBAC Outcomes – Positive Recommendation

Drug and Form	Drug Use and Type	Listing Requested by Sponsor	PBAC Recommendation
<p>Quadrivalent Human Papillomavirus recombinant vaccine, (Types 6, 11, 16, 18), injection, Gardasil[®], CSL Pharmaceuticals Minor submission</p>	<p>Vaccine</p>	<p>For inclusion on the National Immunisation Program for 12 year old girls and a catch-up program for all girls and women 13-26 years.</p>	<p>The PBAC recommended that a school-based program (for 12 to 18 year-old girls) be implemented under the National Immunisation Program (NIP) on the basis of a high, but acceptable cost-effectiveness ratio resulting from a price reduction. Following further negotiations, the PBAC subsequently recommended funding of the 18-26 year cohort on the NIP, as a catch-up program for a period of 2 years.</p>